Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings

Experimental Hematology

Volumn 41, Issue 5, 2013, Pages 491-500

  Yu, Violeta ^a   Pistillo, Jeanne ^a   Archibeque, Ivonne ^a   Han Lee, Josie ^a   Sun, Bee Chun ^a   Schenkel, Laurie B ^a   Geuns Meyer, Stephanie ^a   Liu, Liqin ^a   Emkey, Renee ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; PROTEIN KINASE TYK2; STAT5 PROTEIN; TOFACITINIB; TRANSCRIPTION FACTOR ETV6;

ARTICLE; CELL PROLIFERATION; CELL STRAIN BA/F3; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; ENZYME PURIFICATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; JANUS KINASE 2; LEUKOCYTES, MONONUCLEAR; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PRECURSOR CELLS, B-LYMPHOID; PROTEIN KINASE INHIBITORS; REPRODUCIBILITY OF RESULTS; STAT5 TRANSCRIPTION FACTOR;

EID: 84876869483     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.01.005     Document Type: Article

References (32)

1. Cohen P. Protein kinases-the major drug targets of the twenty-first century?. Nat Rev Drug Discov 2002, 1:309-315.
2. Fedorov O., Müller S., Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010, 6:166-169.
3. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351:95-105.
4. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
5. Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006, 2:358-364.
6. Zuccotto F., Ardini E., Casale E., Angiolini M. Through the " gatekeeper door" : exploiting the active kinase conformation. J Med Chem 2010, 53:2681-2694.
7. Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
8. Goldstien D.M., Gray N.S., Zarrinkar P.P. High-throughput kinase profiling as a platform for drug discovery. Nat Rev Drug Discov 2008, 7:391-397.
9. Ma H., Deacon S., Horiuchi K. The challenge of selecting protein kinase assays for lead discovery optimization. Expert Opin Drug Dis 2008, 3:607-621.
10. Card A., Caldwell C., Min H., et al. High-throughput biochemical kinase selectivity assays: Panel development and screening. J Biomol Screen 2009, 14:31-42.
11. Wernig G., Kharas M.G., Okabe R., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
12. Quintás-Cardama A., Vaddi K., Liu P., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
13. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009, 636-642.
14. Wrobleski S.T., Pitts W.J. Advances in the discovery of small molecule JAK3 inhibitors. Annual reports in medicinal chemistry volume 44 2009, 247-264. San Diego: Academic Press. J.E. Macor (Ed.).
15. Pesu M., Laurence A., Kishore N., et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008, 223:132-142.
16. Rodig S.J., Meraz M.A., White J.M., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
17. Neubauer H., Cumano A., Müller M., et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
18. Parganas E., Wang D., Stravopodis D., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385-395.
19. Thomis D.C., Gurniak C.B., Tivol E., et al. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995, 270:794-797.
20. Nosaka T., van Deursen J.M.A., Tripp R.A., et al. Defective lymphoid development in mice lacking Jak3. Science 1995, 270:800-802.
21. Karaghiosoff M., Neubauer H., Lassnig C., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000, 13:549-560.
22. Stoiber D., Kovacic B., Schuster C., et al. TYK2 is a key regulator of the surveillance of B lymphoid tumors. J Clin Invest 2004, 114:1650-1658.
23. Wilks A.F. The JAK kinases: not just another kinase drug discovery target. Semin Cell Dev Biol 2008, 19:319-328.
24. Pardanani A., Lasho T., Smith G., et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009, 23:1441-1445.
25. Warmuth M., Kim S., Gu X.J., et al. Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 2007, 19:55-60.
26. Lacronique V., Boureux A., Monni R., et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000, 95:2076-2083.
27. Fomenko I., Durst M., Balaban D. Robust regression for high throughput drug screening. Comput Meth Prog Bio 2006, 82:31-37.
28. Flanagan M.E., Blumenkopf T.A., Brissette W.H., et al. Discovery of CP-690,550: a potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune disease and organ transplant rejection. J Med Chem 2010, 53:8468-8484.
29. Erdman D., Allard B., Bohn J., et al. Kinetic study of human full-length wild-type JAK2 and V617F mutant proteins. Open Enzyme Inhibition J 2008, 1:80-84.
30. Knight Z.A., Shokat K.M. Features of selective kinase inhibitors. Chem Biol 2005, 12:621-637.
31. Schenkel L.B., Huang X., Cheng A., et al. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors. J Med Chem 2011, 54:8440-8450.
32. Tefferi A. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. Blood 2012, 119:2721-2730.